Oruka Therapeutics, Inc., a biotechnology company focused on treatments for chronic skin diseases, has announced the promotion of Laura Sandler to Chief Operating Officer. Sandler, who joined Oruka in 2024 as SVP of Operations, has extensive experience in biopharmaceutical leadership and has been instrumental in advancing the company's clinical programs. Prior to Oruka, she held senior roles at CRISPR Therapeutics, MedImmune, Quintiles, Novartis, and bluebird bio.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.